Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Gedeon Richter Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with bipolar I disorder.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cariprazine 3-12 mg/day for 16 weeks | Experimental | Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cariprazine | Drug | Cariprazine was supplied in capsules. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in the YMRS Total Score at Week 16 | The Young Mania Rating Scale (YMRS) is an 11-item scale that assesses manic symptoms based on the patient's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11 items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of each item is rated on a 5-point (0-4) or a 9-point (0-8) scale. The total score of all 11 items can range from 0 to 60. A higher score indicates worse manic symptoms. A negative change score indicates improvement. | Baseline to Week 16 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in the MADRS Total Score at Week 16 | The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician-rated scale that evaluates the patient's depressive symptomatology during the previous week. Patients are rated on 10 items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point (0-6) scale. The total score can range from 0 to 42. A higher score indicates greater depressive symptomatology. A negative change score indicates improvement. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Elizabeth Diaz, MD | Forest Laboratories | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Forest Investigative Site 015 | Springdale | Arkansas | 72764 | United States | ||
| Forest Investigative Site 010 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28843918 | Derived | Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, Nemeth G. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. J Affect Disord. 2018 Jan 1;225:350-356. doi: 10.1016/j.jad.2017.08.040. Epub 2017 Aug 18. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Cariprazine 3-12 mg/Day for 16 Weeks | Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline to Week 16 |
| Carson |
| California |
| 90746 |
| United States |
| Forest Investigative Site 020 | Cerritos | California | 90703 | United States |
| Forest Investigative Site 009 | Escondido | California | 92025 | United States |
| Forest Investigative Site 004 | Garden Grove | California | 92845 | United States |
| Forest Investigative Site 016 | San Diego | California | 92102 | United States |
| Forest Investigative Site 007 | Santa Ana | California | 92701 | United States |
| Forest Investigative Site 023 | Washington D.C. | District of Columbia | 20016 | United States |
| Forest Investigative Site 001 | Bradenton | Florida | 34208 | United States |
| Forest Investigative Site 006 | Fort Lauderdale | Florida | 33308 | United States |
| Forest Investigative Site 013 | Kissimmee | Florida | 34741 | United States |
| Forest Investigative Site 021 | Rockville | Maryland | 20850 | United States |
| Forest Investigative Site 024 | Flowood | Mississippi | 39232 | United States |
| Forest Investigative Site 022 | Creve Coeur | Missouri | 63141 | United States |
| Forest Investigative Site 003 | Saint Charles | Missouri | 63301 | United States |
| Forest Investigative Site 025 | St Louis | Missouri | 63118 | United States |
| Forest Investigative Site 012 | Las Vegas | Nevada | 89102 | United States |
| Forest Investigative Site 002 | Willingboro | New Jersey | 08046 | United States |
| Forest Investigative Site 005 | Cincinnati | Ohio | 45219 | United States |
| Forest Investigative Site 011 | Oklahoma City | Oklahoma | 73112 | United States |
| Forest Investigative Site 017 | Austin | Texas | 78731 | United States |
| Forest Investigative Site 014 | Austin | Texas | 78754 | United States |
| Forest Investigative Site 018 | DeSoto | Texas | 75115 | United States |
| Forest Investigative Site 019 | Houston | Texas | 77008 | United States |
| Forest Investigative Site 309 | Gyula | Bekes County | 5700 | Hungary |
| Forest Investigative Site 301 | Budapest | 1083 | Hungary |
| Forest Investigative Site 302 | Budapest | 1135 | Hungary |
| Forest Investigative Site 306 | Nyíregyháza | 4400 | Hungary |
| Forest Investigative Site 308 | Szombathely | 9700 | Hungary |
| Forest Investigative Site 402 | Tuszyn | Kodz | 95-080 | Poland |
| Forest Investigative Site 404 | Katowice | Silesian | 40-340 | Poland |
| Forest Investigative Site 407 | Gdansk | 80-952 | Poland |
| Forest Investigative Site 408 | Gmina Świecie | 86-100 | Poland |
| Forest Investigative Site 401 | Gorlice | 38-300 | Poland |
| Forest Investigative Site 505 | Barcelona | 08036 | Spain |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Safety population: All enrolled participants who took at least 1 dose of investigational product.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Cariprazine 3-12 mg/Day for 16 Weeks | Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Weight | Mean | Standard Deviation | kg |
| |||||||||||||||||
| Body Mass Index (BMI) | Mean | Standard Deviation | kg/m^2 |
| |||||||||||||||||
| Waist circumference | Mean | Standard Deviation | cm |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in the YMRS Total Score at Week 16 | The Young Mania Rating Scale (YMRS) is an 11-item scale that assesses manic symptoms based on the patient's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11 items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of each item is rated on a 5-point (0-4) or a 9-point (0-8) scale. The total score of all 11 items can range from 0 to 60. A higher score indicates worse manic symptoms. A negative change score indicates improvement. | Intent-to-treat population: All enrolled participants who took at least 1 dose of investigational product and who had a Baseline and at least 1 post-baseline assessment of the Young Mania Rating Scale. | Posted | Mean | Standard Deviation | Units on a scale | Baseline to Week 16 |
|
|
| |||||||||||||||||||||||||
| Secondary | Change From Baseline in the MADRS Total Score at Week 16 | The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician-rated scale that evaluates the patient's depressive symptomatology during the previous week. Patients are rated on 10 items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point (0-6) scale. The total score can range from 0 to 42. A higher score indicates greater depressive symptomatology. A negative change score indicates improvement. | Intent-to-treat population: All enrolled participants who took at least 1 dose of investigational product and who had a Baseline and at least 1 post-baseline assessment of the Young Mania Rating Scale. | Posted | Mean | Standard Deviation | Units on a scale | Baseline to Week 16 |
|
|
Not provided
Safety population: All enrolled participants who took at least 1 dose of investigational product.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Cariprazine 3-12 mg/Day for 16 Weeks | Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator. | 0 | 402 | 34 | 402 | 293 | 402 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Mania | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Akathisia | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Suicidal ideation | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Suicide attempt | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Angina pectoris | Cardiac disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Bipolar I disorder | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Bradycardia | Cardiac disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Dermal cyst | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (14.1) | Systematic Assessment |
| |
| Hypersensitivity | Immune system disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Intentional overdose | Injury, poisoning and procedural complications | MedDRA (14.1) | Systematic Assessment |
| |
| Non-cardiac chest pain | Respiratory, thoracic and mediastinal disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Panic attack | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Paranoia | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA (14.1) | Systematic Assessment |
| |
| Social stay hospitalization | Social circumstances | MedDRA (14.1) | Systematic Assessment |
| |
| Tremor | Nervous system disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Large intestinal obstruction/Large bowel obstruction | Gastrointestinal disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Psychotic disorder/Increased psychosis | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Psychotic disorder/Psychosis | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Mania/Increased mania | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Mania/Worsening of mania | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Constipation | Gastrointestinal disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Toothache | Gastrointestinal disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Weight increased | Investigations | MedDRA (14.1) | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Akathisia | Nervous system disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Extrapyramidal disorder | Nervous system disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Sedation | Nervous system disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Tremor | Nervous system disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
| |
| Restlessness | Psychiatric disorders | MedDRA (14.1) | Systematic Assessment |
|
All data generated in this study will be the property of Forest Research Institute, Inc. An integrated clinical and statistical report will be prepared at the completion of the study. Publication of the results by the Investigator will be subject to mutual agreement between the Investigator and Forest Research Institute, Inc.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Willie R. Earley, MD Associate Vice President Clinical Development-CNS | Allergan | 714-246-4500 | IR-CTRegistration@allergan.com |
| ID | Term |
|---|---|
| D000087122 | Mania |
| ID | Term |
|---|---|
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C533287 | cariprazine |
Not provided
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|